BGT007H cells for advanced digestive cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new cell therapy called BGT007H for people with advanced digestive tract cancers (esophagus, stomach, pancreas, or colon) that have not responded to or stopped working after at least two prior treatments. The goal is to see if this therapy can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to 70 years old.
- You must have a digestive tract cancer (esophagus, stomach, pancreas, or colorectum) that has spread or returned and did not respond to at least two prior standard treatments.
- A sample of your tumor (from a biopsy or stored tissue) must show a specific protein target that the therapy is designed to attack.
- You must have at least one tumor that can be measured on a scan.
- You need to be in fairly good general health, with adequate organ function (like blood counts, liver, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called BGT007 for people with advanced cancers of the digestive system (esophagus, stomach, pancreas, or colon) that have not responded to standard treatments. The therapy uses your own immune cells, modified to target a protein on your cancer cells.
This trial is testing a new cell therapy called BGT007 for people with advanced pancreatic or colorectal cancer that has not responded to other treatments. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
This trial tests a new type of cell therapy (BGT007H cells) for people with advanced gastrointestinal cancers that have not responded to at least two standard treatments. The therapy uses your own immune cells that are modified to target and attack the cancer.
This trial tests a new cell therapy (BGT007H) for people with advanced pancreatic cancer that has not responded to earlier treatments. The goal is to see if it is safe and can help shrink or control the cancer.
This trial tests a new therapy called CT0494BCP for advanced stomach cancer (including cancers at the junction between the esophagus and stomach) that hasn't responded to at least two prior treatments. The therapy is designed to target a specific protein called CLDN18.2 found on your cancer cells, combined with immune-boosting treatment.
This trial tests an injection of your own immune cells (tumor-infiltrating lymphocytes) to see if they can fight advanced solid tumors like stomach or lung cancer. Doctors will remove one of your tumors, grow the immune cells from it, and then give them back to you.
Hear when a new Digestive Tract Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.